Oncolytics Biotech (ONC) Stock Price, News & Analysis

Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Key Stats

• Today's Range: C$14.90 to C$14.90
• 50-Day Range: C$1.17 to C$18.60
• 52-Week Range: C$0.44 to C$2.08
• Volume: 280 shs
• Average Volume: 169,589 shs
• Market Capitalization: C$1.50 billion
• P/E Ratio: N/A
• Dividend Yield: 0.31%
• Price Target: N/A
• Consensus Rating: Buy

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed this year?

Oncolytics Biotech's stock was trading at C$1.33 at the beginning of the year. Since then, ONC stock has increased by 1,020.3% and is now trading at C$14.90.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (TSE:ONC) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01.

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and

Company Calendar

• Last Earnings: 11/12/2024
• Today: 10/06/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:ONC
• CIK: N/A
• Web: www.oncolyticsbiotech.com
• Phone: +1-403-6707380
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$27.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -141.94%
• Return on Assets: -71.33%

Debt

• Debt-to-Equity Ratio: 11.75
• Current Ratio: 2.99
• Quick Ratio: 8.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$3.53 per share
• Price / Cash Flow: 4.22
• Book Value: C$0.12 per share
• Price / Book: 126.70

Miscellaneous

• Outstanding Shares: 100,361,000
• Free Float: N/A
• Market Cap: C$1.50 billion
• Optionable: Not Optionable
• Beta: 0.80